FDA OKs new AI-based breast, prostate cancer tools from RadNet

2019 08 29 18 18 5039 Quality Check Mark 400

The U.S. Food and Drug Administration (FDA) has given 510(k) clearance to artificial intelligence (AI)-based breast and prostate cancer detection tools from RadNet's subsidiaries DeepHealth and Quantib.

DeepHealth's Saige-Dx is a more advanced successor to the company's Saige-Q worklist triage software. It uses AI to automatically identify suspicious lesions in mammograms and assigns a suspicion level to each finding and the entire case.

Quantib Prostate 2.0 is an AI-based software solution that advances an MRI prostate reporting workflow and offers a suite of tools, including AI-based segmentation and volumetry, precise registration and movement correction, one-click segmentation of lesion candidates, PI-RADS scoring support, and standardized reporting.

Page 1 of 367
Next Page